Indications and uses
helps prevent sunburn higher SPF gives more sunburn protection provides moderate protection against sunburn
LBel Paris
- Manufacturer
- Ventura International LTD
- Effective date
- 2010-08-10
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-05-31 22:25:32
Label at a glance#
ProductLBel Paris Regression Jour
Active ingredientOctinoxate, Octisalate, Oxybenzone
Label structure10 sections
Dosage and administration
apply smoothly every morning before sun exposure and as needed. apply after cleansing and toning on face and neck. children under 6 months of age: ask a doctor.
Storage and handling
Moderate sun protection product. Sun alert: Limiting sun exposure, wearing protective clothing, and using sunscreens may reduce the risk of skin cancer, and other harmful effects of the sun.
Label contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
Drug Facts
Active Ingredients
Octinoxate (7.5 %), Octisalate (4 %), Oxybenzone (4 %)
Purpose
Sunscreen
Uses
- helps prevent sunburn
- higher SPF gives more sunburn protection
- provides moderate protection against sunburn
Warnings
- For external use only.
OTC - WHEN USING SECTION
When using this product
- keep out of eyes. Rinse with water to remove.
OTC - STOP USE SECTION
Stop use and ask a doctor if
- rash and irritation develops and lasts.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
- Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
Directions
- apply smoothly every morning before sun exposure and as needed.
- apply after cleansing and toning on face and neck.
- children under 6 months of age: ask a doctor.
Other information
- Moderate sun protection product.
- Sun alert: Limiting sun exposure, wearing protective clothing, and using sunscreens may reduce the risk of skin cancer, and other harmful effects of the sun.
Inactive ingredients
Aqua (water), glycine soja (soybean) protein, c12-15 alkyl benzoate, pisum sativum (pea) extract, cyclohexasiloxane, dimethicone, mannitol, cetearyl alcohol, glyceryl stearate, hdi/ trimethylol hexyllactone crosspolymer, phenoxyethanol, sodium acrylate/ acryloyldimethyltaurate/ dimethylacrylamide crosspolymer, c20-22 alkyl phosphate, hydroxyethyl acrylate/ sodium acryloyldymethyl taurate copolymer, c20-22 alcohols, triethanolamine, isohexadecane, methylparaben, c14-22 alcohols, cetearyl glucoside, hydrolyzed adansonia digitata extract, butylparaben, cyclopentasiloxane, chlorphenesin, propylparaben, xanthan gum, disodium edta, acrylates/c10-30 alkyl acrylate crosspolymer, parfum (fragance), sorbic acid, polysorbate 60, cyclodextrin, c12-20 alkyl glucoside, faex extract (yeast extract), hydrolyzed algin, ethylparaben, chlorella vulgaris extract, maris aqua (sea water), isobutylparaben, silica, disodium succinate, ci42090 (blue 1).
SPL UNCLASSIFIED SECTION
US: Distributed by Ventura International, Ltd. San Francisco, CA 94111
PRINCIPAL DISPLAY PANEL - 50 ml Carton
L'BEL
PARIS
REGRESSION
JOUR
protective complex against
the first signs of age
with spf 15 facial day lotion
normal to combination skin
50 ml e (1.6 fl.oz.)
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| a62a50ac-1535-4461-9768-8ae703e2e9fb | Product name | 1 | 20210525 |
| 9514609b-a2a9-f8ec-6ba6-3f8e5ee89877 | Product name | 1 | 20140508 |
| bc07ef78-e82d-0c19-31f4-31f263780582 | Product name | 1 | 20140508 |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 14783-035-41 | 2019-10-21 | C162847 | 48780-1 | 956f9ecf-c4ad-621f-e053-dbdaa90a74ad | L'BEL PARIS REGRESSION JOUR |
| 14783-045-51 | 2019-10-21 | C162847 | 48780-1 | 956f9ecf-c4ad-621f-e053-dbdaa90a74ad | L'BEL PARIS REGRESSION JOUR |
| 14783-055-61 | 2019-10-21 | C162847 | 48780-1 | 956f9ecf-c4ad-621f-e053-dbdaa90a74ad | L'BEL PARIS REGRESSION JOUR |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 14783-035-41 | LBel Paris Regression Jour | 1 in 1 BOX | CREAM | 1 | 1 | |
| 14783-035-42 | LBel Paris Regression Jour | 1 g in 1 JAR | CREAM | 1 | 1 | |
| 14783-045-51 | LBel Paris Regression Jour | 1 in 1 BOX | CREAM | 1 | 1 | |
| 14783-045-52 | LBel Paris Regression Jour | 5 g in 1 JAR | CREAM | 5 | 1 | |
| 14783-055-61 | LBel Paris Regression Jour | 1 in 1 BOX | CREAM | 1 | 1 | |
| 14783-055-66 | LBel Paris Regression Jour | 50 g in 1 JAR | CREAM | 50 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 14783-035 | LBEL PARIS (OCTINOXATE, OCTISALATE, AND OXYBENZONE) CREAM [VENTURA INTERNATIONAL LTD] | 1 | Legacy NDC, 2 package rows | 20100815_132ef4d4-8554-4e37-89a9-c9b5db96cc13.zip |
| 14783-045 | LBEL PARIS (OCTINOXATE, OCTISALATE, AND OXYBENZONE) CREAM [VENTURA INTERNATIONAL LTD] | 1 | Legacy NDC, 2 package rows | 20100815_132ef4d4-8554-4e37-89a9-c9b5db96cc13.zip |
| 14783-055 | LBEL PARIS (OCTINOXATE, OCTISALATE, AND OXYBENZONE) CREAM [VENTURA INTERNATIONAL LTD] | 1 | Legacy NDC, 2 package rows | 20100815_132ef4d4-8554-4e37-89a9-c9b5db96cc13.zip |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Octinoxate | ACTIVE INGREDIENT | 4Y5P7MUD51 | 1 | |
| Octisalate | ACTIVE INGREDIENT | 4X49Y0596W | 1 | |
| Oxybenzone | ACTIVE INGREDIENT | 95OOS7VE0Y | 1 | |
| Octinoxate | ACTIVE MOIETY | 4Y5P7MUD51 | 1 | |
| Octisalate | ACTIVE MOIETY | 4X49Y0596W | 1 | |
| Oxybenzone | ACTIVE MOIETY | 95OOS7VE0Y | 1 | |
| butylparaben | INACTIVE INGREDIENT | 3QPI1U3FV8 | 1 | |
| c12-15 alkyl benzoate | INACTIVE INGREDIENT | A9EJ3J61HQ | 1 | |
| cetostearyl alcohol | INACTIVE INGREDIENT | 2DMT128M1S | 1 | |
| chlorphenesin | INACTIVE INGREDIENT | I670DAL4SZ | 1 | |
| cyclomethicone 5 | INACTIVE INGREDIENT | 0THT5PCI0R | 1 | |
| cyclomethicone 6 | INACTIVE INGREDIENT | XHK3U310BA | 1 | |
| dimethicone | INACTIVE INGREDIENT | 92RU3N3Y1O | 1 | |
| edetate disodium | INACTIVE INGREDIENT | 7FLD91C86K | 1 | |
| ethylparaben | INACTIVE INGREDIENT | 14255EXE39 | 1 | |
| FD&C blue no. 1 | INACTIVE INGREDIENT | H3R47K3TBD | 1 | |
| glyceryl monostearate | INACTIVE INGREDIENT | 230OU9XXE4 | 1 | |
| isobutylparaben | INACTIVE INGREDIENT | 0QQJ25X58G | 1 | |
| isohexadecane | INACTIVE INGREDIENT | 918X1OUF1E | 1 | |
| mannitol | INACTIVE INGREDIENT | 3OWL53L36A | 1 | |
| methylparaben | INACTIVE INGREDIENT | A2I8C7HI9T | 1 | |
| phenoxyethanol | INACTIVE INGREDIENT | HIE492ZZ3T | 1 | |
| polysorbate 60 | INACTIVE INGREDIENT | CAL22UVI4M | 1 | |
| propylparaben | INACTIVE INGREDIENT | Z8IX2SC1OH | 1 | |
| silicon dioxide | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 | |
| snow pea | INACTIVE INGREDIENT | 84SKC33B1I | 1 | |
| sodium succinate anhydrous | INACTIVE INGREDIENT | V8ZGC8ISR3 | 1 | |
| sorbic acid | INACTIVE INGREDIENT | X045WJ989B | 1 | |
| soybean | INACTIVE INGREDIENT | L7HT8F1ZOD | 1 | |
| trolamine | INACTIVE INGREDIENT | 9O3K93S3TK | 1 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 1 | |
| xanthan gum | INACTIVE INGREDIENT | TTV12P4NEE | 1 | |
| yeast | INACTIVE INGREDIENT | 3NY3SM6B8U | 1 |
Products#
Every source-derived product name is available through these pages.
- LBel Paris Regression Jour
- Octinoxate, Octisalate, and Oxybenzone
- Octinoxate
- Octisalate
- Oxybenzone
- water
- soybean
- c12-15 alkyl benzoate
- snow pea
- cyclomethicone 6
- dimethicone
- mannitol
- cetostearyl alcohol
- glyceryl monostearate
- phenoxyethanol
- trolamine
- isohexadecane
- methylparaben
- butylparaben
- cyclomethicone 5
- chlorphenesin
- propylparaben
- xanthan gum
- edetate disodium
- sorbic acid
- polysorbate 60
- yeast
- ethylparaben
- isobutylparaben
- silicon dioxide
- sodium succinate anhydrous
- FD&C blue no. 1
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 14783-055 | 14783-055-66, 14783-055-61 |
| 14783-045 | 14783-045-52, 14783-045-51 |
| 14783-035 | 14783-035-42, 14783-035-41 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| mannitol | MANNITOL | 3OWL53L36A | GRANULE / ORAL | 1328 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | TABLET / ORAL | 100 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | PASTE, DENTIFRICE / DENTAL | NA | ||
| mannitol | MANNITOL | 3OWL53L36A | SUSPENSION / OPHTHALMIC | 9 mg | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 2 mg | ||
| cetostearyl alcohol | CETOSTEARYL ALCOHOL | 2DMT128M1S | CREAM / TOPICAL | 1428 mg | ||
| butylparaben | BUTYLPARABEN | 3QPI1U3FV8 | CREAM / TOPICAL | 0.4 %w/w | ||
| butylparaben | BUTYLPARABEN | 3QPI1U3FV8 | LOTION / TOPICAL | 4 mg | ||
| polysorbate 60 | POLYSORBATE 60 | CAL22UVI4M | GUM, CHEWING / BUCCAL | 5 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 3.6 mg | ||
| trolamine | TROLAMINE | 9O3K93S3TK | AEROSOL, METERED / RECTAL | ADJ PH | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION / AURICULAR (OTIC) | 0.01 %w/v | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | SPRAY / NASAL | 1 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION / SUBCUTANEOUS | 6 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION, EXTENDED RELEASE / ORAL | 4 mg | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | SUPPOSITORY / RECTAL | 14 mg | ||
| butylparaben | BUTYLPARABEN | 3QPI1U3FV8 | TABLET, EXTENDED RELEASE / ORAL | 0.01 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SOLUTION, CONCENTRATE / ORAL | 1 mg/1ml | ||
| mannitol | MANNITOL | 3OWL53L36A | SOLUTION, GEL FORMING, EXTENDED RELEASE / OPHTHALMIC | 4.35 %w/w | ||
| mannitol | MANNITOL | 3OWL53L36A | INJECTION, SOLUTION / SUBMUCOSAL | 2.94 %w/v | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SUSPENSION/ DROPS / OPHTHALMIC | 0.05 %w/w | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | CONCENTRATE / ORAL | 12 mg | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | POWDER, FOR SOLUTION / ORAL | 10 mg/5ml | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE / ORAL | 5000 mg | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER / RESPIRATORY (INHALATION) | NA | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | ELIXIR / ORAL | 200 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION / AURICULAR (OTIC) | NA | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | GEL / TOPICAL | 24 mg | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / RESPIRATORY (INHALATION) | NA | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION / RECTAL | 271 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | POWDER / ORAL | 4352 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SOLUTION / RECTAL | 0.13 %w/v | ||
| trolamine | TROLAMINE | 9O3K93S3TK | GEL, METERED / TOPICAL | 20 mg | ||
| cyclomethicone 5 | CYCLOMETHICONE 5 | 0THT5PCI0R | AEROSOL / TOPICAL | 2.5 %w/w | ||
| mannitol | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SOLUTION / PARENTERAL | 200 mg | ||
| FD&C blue no. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | SOLUTION / DENTAL | NA | ||
| polysorbate 60 | POLYSORBATE 60 | CAL22UVI4M | SHAMPOO / TOPICAL | 14.55 %w/w | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | LOZENGE / ORAL | 120 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | DROPS / AURICULAR (OTIC) | 0.05 %w/w | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | INJECTION / SOFT TISSUE | 0.15 %w/v | ||
| xanthan gum | XANTHAN GUM | TTV12P4NEE | TABLET / ORAL | 56 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | INJECTION, SOLUTION / INTRAVENOUS | 15400 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION / SUBCUTANEOUS | 0.02 %w/v | ||
| FD&C blue no. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | CAPSULE, COATED PELLETS / ORAL | NA | ||
| mannitol | MANNITOL | 3OWL53L36A | WAFER / ORAL | 642 mg | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | SUPPOSITORY / VAGINAL | NA | ||
| propylparaben | PROPYLPARABEN | Z8IX2SC1OH | FILM, SOLUBLE / BUCCAL | 1 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SOLUTION / RESPIRATORY (INHALATION) | 0.03 %w/w | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / RECTAL | 97 mg | ||
| polysorbate 60 | POLYSORBATE 60 | CAL22UVI4M | CREAM / VAGINAL | 200 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | AEROSOL, FOAM / VAGINAL | 0.1 %w/w | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | TABLET, CHEWABLE / ORAL | 1 mg | ||
| FD&C blue no. 1 | FD&C BLUE NO. 1 | H3R47K3TBD | MOUTHWASH / BUCCAL | NA | ||
| butylparaben | BUTYLPARABEN | 3QPI1U3FV8 | CAPSULE, EXTENDED RELEASE / ORAL | NA | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION, SUSPENSION / SOFT TISSUE | 1 mg | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | SUPPOSITORY / VAGINAL | NA | ||
| methylparaben | METHYLPARABEN | A2I8C7HI9T | OINTMENT / OPHTHALMIC | 0.05 %w/w | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION, SUSPENSION / INTRA-ARTICULAR | 1 mg | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / ORAL | 300 mg | ||
| glyceryl monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | LOTION / TOPICAL | 177 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 4922ce2e-1697-4239-a440-41c84aa55b30 | 132ef4d4-8554-4e37-89a9-c9b5db96cc13 | 2010-08-10 | Warnings | 4922ce2e-1697-4239-a440-41c84aa55b30 132ef4d4-8554-4e37-89a9-c9b5db96cc13 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.